Renal Failure Clinical Trial
Official title:
The Vienna Prograf and Endothelial Progenitor Cell Extension Study
Conversion of renal transplant recipients from either tacrolimus or cyclosporin A to tacrolimus modified release to investigate the effects of the MDR1/CYP450 genotype on the trough blood levels of tacrolimus with modified galenic (tacrolimus MR4; Advagraf®).
The study concerns the conversion of immunosuppressive agents among participants in the
clinical trial "The Vienna Prograf and Endothelial Progenitor Cell Study - The Vienna PEP
Study" at the end of the study after 2 years in the extension study PEP-X.
The aim of the conversion is to investigate the effects of the multi-drug resistance (MDR1,
gene symbol ABCB1) genotype on the trough blood levels of tacrolimus modified release (TAC
MR4; Advagraf®). Analyzes of the effects of the genotype on the concentration/dose ratio
([ng/mL]/[mg/d]) will be carried out, as well as studies on existing polymorphisms in the
MDR1 gene. The written informed consent to conversion of either tacrolimus (TAC; Prograf®) or
cyclosporin A (CSA; Sandimmun Neoral®) to TAC MR4 will be obtained.
Upon completion of 24 months of study participation of the PEP-study, and consent to convert
the immunosuppressant therapy of either TAC or CSA to TAC MR4, it will be used as indicated
by the manufacturer. In patients treated with CSA, the initial dose will be 0.1-0.12 mg TAC
MR4 per kg of body weight per day with oral morning administration. In patients who are
already treated with TAC, the conversion to TAC MR4 will be performed in a 1:1 ratio.
The dosage data for the conversion of CSA to TAC MR4 are taken from the documents of the
European Medicines Agency homepage (http://www.emea.europa.eu/index/ indexh1.htm, retrieved
26.09.2007), those on the safety and equivalence of the achieved areas under the curve (AUC)
of both TAC formulations from Alloway et al. (Transplant Proc 2005; 37: 867-870).
The conversion will be performed by Univ. Prof. Dr. Gere Sunder-Plassmann, and Dr. Markus
Riegersperger, respectively, both Division of Nephrology and Dialysis, Department of Medicine
III, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna. The desired trough
level is set at 4.0-8.0ng/mL according to the usual clinical standards for long-term
transplant patients at the investigators center. The trough level analyses are performed at
the Medical University of Vienna, according to the following schedule: 1 week after
conversion, 2 weeks after conversion, 4 weeks after conversion, 12 weeks and 12 months after
conversion.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02763410 -
Impact of the Composition of Packed Red Blood Cell Supernatant on Renal Dysfunction and Posttransfusion Immunomodulation
|
||
| Active, not recruiting |
NCT03183245 -
Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis
|
Phase 3 | |
| Completed |
NCT04084301 -
Impact of Cardiopulmonary Bypass Flow on Renal Oxygenation, Blood Flow and Tubular Injury
|
N/A | |
| Completed |
NCT03292029 -
Pilot Medical Evaluation of the T50 Test
|
N/A | |
| Suspended |
NCT04589065 -
SCD for CRS in Congestive Heart Failure (CHF) (No Left Ventricular Assist Device)
|
N/A | |
| Completed |
NCT03806998 -
Effects of a Ketoacid Supplementation in Patients With Stage III to IV Renal Failure
|
Phase 3 | |
| Active, not recruiting |
NCT03672110 -
Slow and Low Start of a Tacrolimus Once Daily Immunosuppressive Regimen
|
Phase 3 | |
| Completed |
NCT02325726 -
RRI Compared With NephroCheckTM to Predict Acute Renal Failure After Cardiac Surgery.
|
N/A | |
| Completed |
NCT02116270 -
Accelerated Immunosenescence and Chronic Kidney Disease
|
N/A | |
| Completed |
NCT01859273 -
Adherence Enhancement for Renal Transplant Patients
|
N/A | |
| Completed |
NCT01388270 -
Effect of a Pre Heparin Coated Dialysis Filter on Coagulation During Hemodialysis
|
Phase 4 | |
| Completed |
NCT01187953 -
Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx
|
Phase 3 | |
| Completed |
NCT00966615 -
The Effect of Neutral Peritoneal Dialysis (PD) Solution With Minimal Glucose-Degradation-Product (GDP) on Fluid Status and Body Composition
|
Phase 4 | |
| Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
| Completed |
NCT01008631 -
The Pharmacologic Profile of Sodium Thiosulfate in Renal Failure and Healthy Volunteers
|
N/A | |
| Completed |
NCT00737672 -
GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis
|
Phase 3 | |
| Completed |
NCT00765661 -
Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients
|
Phase 2 | |
| Completed |
NCT00808691 -
Microcirculation and Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit
|
N/A | |
| Recruiting |
NCT00470769 -
The Efficacy of Color-Doppler Ultrasonography to Assess the Renal Blood Flow With the Estimation of GFR
|
N/A | |
| Terminated |
NCT00338455 -
Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC
|
Phase 2 |